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Abstract
Aim: Polycystic	ovary	syndrome	(PCOS)	is	an	ovulatory	disorder	and	insulin	resistance	
and	diabetes	are	involved	in	 its	pathophysiology.	Metformin,	an	anti-	diabetic	agent,	
has	been	reported	to	be	useful	to	induce	ovulation.
Methods: Metformin	 treatment	 was	 classified	 into	 four	 types:	 (1)	 clomiphene–	
metformin	combination	treatment	for	clomiphene-	resistant	patients;	(2)	clomiphene–
metformin	combination	for	clomiphene-	sensitive	patients;	(3)	clomiphene–metformin	
combination	for	naïve	patients;	and	(4)	metformin	monotherapy.	The	patients	under-
went	 physical,	 endocrinological,	 and	 clinical	 examinations	 for	 their	 ovulation	 rates,	
pregnancy	rates,	and	follicular	development.
Results: The	ovulation	rates,	pregnancy	rates,	and	single	follicular	development	were	
not	significantly	different	among	the	clomiphene–metformin	combination	treatment	
groups.	In	the	Body	Mass	Index	(BMI)	subanalysis,	the	pregnancy	rate	was	higher	in	
the	BMI≥30	kg/m2	group	than	in	the	other	three	groups	with	a	BMI	of	≤30	kg/m2 in 
both	 cycles	 and	 cases.	 The	 ovulation	 rates	 and	 pregnancy	 rates	were	 significantly	
higher	in	the	group	with	a	fasting	insulin	of	≥15	μU/mL	than	in	the	groups	with	a	fast-
ing	insulin	of	<15	μU/mL	in	both	cycles	and	cases.
Conclusion: Clomiphene–metformin	combination	treatment	appears	to	be	useful,	at	
least	for	clomiphene-	resistant	patients,	and	a	BMI	of	>30	kg/m2	and	a	fasting	insulin	
of	≥15	μU/mL	appear	to	be	predictors	of	a	good	result	with	this	treatment.
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1  | INTRODUCTION
Polycystic	ovary	syndrome	 (PCOS)	 is	an	ovulatory	disorder	 that	 is	char-
acterized	 by	 hyperandrogenism,	 infertility,	 and	 anovulation	 that	 is	 seen	
in	 6%-	10%	 of	women	 of	 reproductive	 age.	 Insulin	 resistance,	 diabetes,	
and	 hypertension	 are	 involved	 in	 the	 pathophysiology	 of	 PCOS,1 and 
metformin,	an	anti-	diabetic	agent,	has	been	reported	to	be	useful	for	induc-
ing	ovulation	in	patients	with	PCOS.	The	Japan	Society	of	Obstetrics	and	
Gynecology,	Reproductive	Endocrine	Committee	 has	 created	 treatment	
guidelines	for	PCOS	and	if	patients	with	PCOS	fail	to	ovulate	by	the	use	of	
clomiphene,	then	clomiphene	plus	metformin	combination	therapy	is	posi-
tioned	as	a	treatment	option.2–4	In	a	meta-	analysis,	clomiphene–metformin	
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combination	therapy	in	clomiphene-	resistant	patients	was	more	effective	
than	clomiphene-	alone	 therapy	 for	ovulation,5	pregnancy,	and	 live	birth	
rates.6	However,	the	therapeutic	effect	of	metformin	in	reproduction	is	not	
established,	as	it	has	been	difficult	to	integrate	the	large	amount	of	clinical	
data	in	one	facility	because	it	is	not	approved	by	insurance	as	an	ovulation	
induction	agent.	This	study	was	carried	out	to	study	the	usefulness	of	ovu-
lation	induction	by	various	metformin	treatments	in	patients	with	PCOS.
2  | MATERIALS AND METHODS
2.1 | Participants
This	study	was	a	retrospective	study	of	metformin	treatments	for	Japanese	
patients	with	PCOS	 for	ovulation	 induction,	using	a	questionnaire	 in	18	
facilities.	 The	 questionnaire	 was	 sent	 to	 Okayama	 University,	 Kurashiki	
Central	 Hospital,	 Kurashiki	 Medical	 Center,	 Okayama	 Couple’s	 Clinic,	
Okayama	 Aiiku	 Clinic,	 Yamaguchi	 University,	 Yamaguchi	 Prefectural	
Grand	Medical	Center,	Saiseikai	Shimonoseki	General	Hospital,	Shimane	
University,	 Shimane	 Prefectural	 Central	 Hospital,	 Matsue	 City	 Hospital,	
Hiroshima	 Prefectural	 Hospital,	 Kinutani	 Women’s	 Clinic,	 Tottori	
University,	 Kochi	University,	 Tokushima	University,	 Sanno	Hospital,	 and	
Mimuro	Women’s	Clinic.	The	metformin	treatment	was	classified	into	four	
types:	(1)	clomiphene–metformin	combination	treatment	for	clomiphene-	
resistant	 patients;	 (2)	 clomiphene–metformin	 combination	 treatment	 for	
clomiphene-	sensitive	 patients;	 (3)	 clomiphene–metformin	 combination	
treatment	for	naïve	patients,	who	have	no	treatment	history	of	clomiphene;	
and	 (4)	 metformin	 monotherapy.	 Each	 type	 was	 examined	 individually. 
Among	a	total	of	178	cases	with	798	cycles	that	were	collected	from	the	
18	facilities,	16	cases	with	318	cycles	were	excluded	as	unsuitable	for	the	
four	treatments.	Thus,	a	total	of	162	cases	with	480	cycles	were	analyzed	
for	their	ovulation	and	pregnancy	rates.	This	study	was	approved	by	the	
Institutional	Ethical	Committee	of	Tokushima	University,	Tokushima,	Japan.
2.2 | Treatments
2.2.1 | Clomiphene–metformin combination for the 
clomiphene- resistant patients
A	total	of	80	clomiphene-	resistant	patients	with	PCOS	with	221	cy-
cles	 underwent	 clomiphene–metformin	 combination	 treatment.	 The	
ovulation	rates	per	cycle	and	per	case,	pregnancy	rates	per	cycle	and	
per	case,	and	the	single	follicular	development	rate	were	analyzed.	In	
addition,	 subanalyses	were	 carried	 out	 according	 to	 the	 Body	Mass	
Index	 (BMI)	 (n=70),	 homeostasis	 model	 assessment-	insulin	 resist-
ance	 (HOMA-	IR)	 (n=39),	 and	 fasting	 insulin	 (n=39)	 levels.	 Seventy	
patients	 who	 had	 BMI	 data	 were	 divided	 into	 four	 subgroups:	 lean	
(BMI<18.5	kg/m2)	(n=9),	normal	(BMI=18.5-	25.0	kg/m2)	(n=30),	over-
weight	 (BMI=25.0-	30.0	kg/m2)	 (n=15),	 and	 obese	 (BMI>30.0	kg/m2)	
(n=16).	 Thirty-	nine	 patients	 who	 had	 HOMA-	IR	 data	 were	 divided	
into	 four	subgroups:	HOMA-	IR<0.8	 (n=6),	HOMA-	IR=0.8-	1.6	 (n=10),	
HOMA-	IR=1.6-	2.5	 (n=6),	 and	 HOMA-	IR>2.5	 (n=17).	 Thirty-	nine	 pa-
tients	who	had	fasting	insulin	data	were	divided	into	two	subgroups:	
<15	μU/mL	fasting	insulin	(n=29)	and	≥15	μU/mL	fasting	insulin	(n=10).
2.2.2 | Clomiphene–metformin combination for the 
clomiphene- sensitive patients
The	clomiphene–metformin	combination	treatment	was	given	to	57	
patients	who	 failed	 at	 least	 three	 cycles	 of	 clomiphene	 therapy	 for	
ovulation	induction.	In	total,	205	cycles	were	analyzed	as	the	clomi-
phene–metformin	 combination	 treatment	 for	 clomiphene-	sensitive	
patients.	The	ovulation	rates	per	cycle	and	per	case,	pregnancy	rates	
per	cycle	and	per	case,	and	the	single	follicular	development	rate	were	
analyzed.	In	addition,	subanalyses	were	carried	out	according	to	the	
BMI	(n=54)	and	HOMA-	IR	(n=37).	Fifty-	five	patients	who	had	BMI	data	
were	divided	into	four	subgroups:	lean	(BMI<18.5	kg/m2)	(n=5),	normal	
(BMI=18.5-	25.0	kg/m2)	 (n=34),	 overweight	 (BMI=25.0-	30.0	kg/m2)	
(n=7),	and	obese	(BMI>30.0	kg/m2)	(n=8).	Thirty-	seven	patients	who	
had	HOMA-	IR	data	were	divided	into	three	subgroups:	HOMA-	IR<1.6	
(n=15),	HOMA-	IR=1.6-	2.5	(n=8),	and	HOMA-	IR>2.5	(n=14).
2.2.3 | Clomiphene–metformin combination for the 
naïve patients
“Naïve”	patients	were	defined	as	having	no	treatment	history	of	clo-
miphene.	 Seven	 cases	 without	 an	 infertility	 treatment	 history	 with	
12	cycles	were	treated	with	the	clomiphene–metformin	combination	
treatment	as	the	first-	line	treatment	for	ovulation	induction.	The	ovu-
lation	rates	per	cycle	and	per	case	and	single	follicular	development	
rates	were	investigated.
2.2.4 | Metformin monotherapy
There	were	18	cases	with	42	cycles	of	metformin	monotherapy.	The	in-
dications	for	this	therapy	were	clomiphene	resistance	(no	ovulation)	in	
six	cases	with	21	cycles,	the	first	choice	for	ovulation	induction	in	five	
cases	with	10	cycles,	habitual	abortion	in	four	cases	with	seven	cycles,	no	
pregnancy	by	clomiphene	in	an	ovulated	cycle	in	one	case	with	one	cycle,	
and	a	high	HOMA-	IR	in	two	cases	with	three	cycles.	Fifteen	cases	were	
subanalyzed	by	HOMA-	IR:	<1.6	(n=3),	1.6-	2.5	(n=5),	and	>2.5	(n=7).
2.3. | Pregnancy and infant outcomes
The	outcomes	of	64	pregnancies	and	29	infants,	abortion	rates,	mul-
tiple	pregnancy	rates,	birth	weights,	birth	weeks,	and	infant	anomalies	
were	studied.
2.4 | Side- effects
The	side-	effects	were	studied	in	each	treatment	group	and	compared	
between	the	clomiphene–metformin	combination	treatments	and	the	
metformin	monotherapy.
2.5 | Dose of metformin, definition of clomiphene 
resistance, and ovulation rate per case
The	usage	of	metformin	and	its	duration	were	determined	by	each	
facility.	 Clomiphene	 resistance	was	 defined	 as	 no	 ovulation	with	
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100	mg	of	 clomiphene,	 or	 at	 least	 two	 cycles.	 The	occurrence	of	
ovulation	per	case	with	multiple	treatment	cycles	was	determined	
when	 ovulation	 was	 observed	 in	 at	 least	 half	 of	 the	 treatment	
cycles.
2.6 | Statistical analysis
A	subanalysis	by	BMI	and	HOMA-	IR	with	treatments	1,	2,	and	3	were	
done	by	using	the	chi	square	test	and	the	Bonferroni	post	hoc	test.	
A	subanalysis	by	fasting	insulin	with	treatment	1	was	done	by	using	
the	chi	 square	 test.	 In	all	 the	analyses,	P<.05	was	considered	 to	be	
significant.
3  | RESULTS
3.1 | Clomiphene–metformin combination treatment 
for the clomiphene- resistant patients
The	mean	 clomiphene	dose	was	126.3±33.1	mg/d	 (mean	±	stand-
ard	 deviation	 [SD]).	 The	 clomiphene	 doses	 were	 150	mg/day	
(47.5%,	 105/221)	 and	 100	mg/d	 (43.8%,	 97/221),	 both	 of	 which	
accounted	 for	 90.6%	 of	 all	 the	 treated	 cycles	 (Table	1,	 Figure	1).	
The	mean	metformin	dose	was	690.1±163.9	mg/d.	The	metformin	
doses	 were	 predominantly	 750	mg/day	 (74.9%,	 164/219)	 in	 all	
the	 cycles.	Most	of	 the	 cycles	 for	 the	metformin-	treated	patients	
(85.8%,	169/197)	were	treated	with	metformin	continuous	admin-
istration	and	the	others	 (14.2%,	28/197)	were	treated	with	short-	
term	metformin	 administration	 from	 the	 fifth	 day	 of	 the	 cycle	 to	
the	day	of	the	human	chorionic	gonadotropin	(hCG)	injection.	The	
ovulation	rate	was	65.1%	per	cycle	and	69.9%	per	case	and	single	
follicular	development	was	achieved	in	81.1%	of	the	cycles	(Table	2,	
Figure	2).	 The	 pregnancy	 rate	was	 9.9%	per	 cycle	 and	 21.9%	per	
case.	 In	 the	 BMI	 subanalysis,	 the	 pregnancy	 rate	 was	 higher	 in	
the	obese	group	than	in	the	other	three	groups	in	both	cycles	and	
cases	(Figure	3).	The	ovulation	rates	and	pregnancy	rates	were	sig-
nificantly	higher	 in	 the	group	with	a	 fasting	 insulin	of	≥15	μU/mL	
than	in	the	group	with	<15	μU/mL	fasting	insulin	in	both	cycles	and	
cases	(P<.05)	(Figure	4).	In	addition,	the	ovulation	rate	per	cycle	was	
73.9%	in	the	HOMA-	IR<0.8	group,	65.5%	in	the	HOMA-	IR=0.8-	1.6	
group,	 50.0%	 in	 the	 HOMA-	IR=1.6-	2.5	 group,	 and	 72.3%	 in	 the	
HOMA-	IR≥2.5	group;	there	was	no	significant	difference	among	the	
groups.	Furthermore,	the	pregnancy	rate	per	cycle	was	5.6%	in	the	
TABLE  1 Background	of	the	participants	by	treatment
Characteristic C+M for CR C+M for CS C+M for naïve M
Cycle 221 205 12 42
Case 80 57 7 18
Age	(years) 29.6±4.0	(21-	38) 31.0±4.5	(22-	43) 29.9±3.7	(26-	36) 33.2±4.7	(25-	40)
Height	(cm) 157.9±5.9	(145-	178) 156.1±4.8	(148-	168) 157.7±5.3	(152-	166) 158.8±5.0	(150-	172)
Weight	(kg) 62.9±16.6	(40-	105.6) 57.5±13.5	(42-	93) 59.6±17.8	(44-	94.7) 70.5±15.5	(53-	114)
Body	mass	index	(kg/m2) 25.2±6.5	(17.3-	45.0) 23.6±5.4	(17.2-	38.7) 23.7±5.8	(18.8-	34.4) 28.0±6.1	(20.9-	46.3)
Rate	of	lean	and	normal	cases	(%) 55.7 72.2 57.1 38.9
(39/70) (39/54) (4/7) (7/18)
Rate	of	overweight	and	obese	cases	(%) 44.3 27.8 42.9 61.1
(31/70) (15/54) (3/7) (11/18)
Age	of	menarche	(years) 12.5±1.6	(10-	18) 12.4±1.4	(10-	15) 12.4±1.1	(11-	14) 12±1.4	(10-	15)
Number	of	gravida 0.6±0.8	(0-	3) 0.8±1.2	(0-	5) 0.0 1.3±1.7	(0-	5)
Number	of	para 0.4±0.6	(0-	2) 0.3±0.5	(0-	2) 0.0 0.2±0.4	(0-	1)
Fasting	glucose	(mg/dL) 92.6±10.4	(70-	127) 97.3±16.6	(82-	176) 89.3±6.4	(82-	93) 97.0±17.1	(72-	145)
Fasting	insulin	(μu/mL) 16.0±32.6	(0.3-	197.8) 10.5±7.1	(2.2-	27.3) 8.2±13.5	(0.34-	23.8) 16.1±23.8	(0.3-	99.3)
HOMA-	IR 4.0±9.0	(0.06-	55.7) 2.7±2.2	(0.5-	8.8) 0.7±0.1	(0.7-	0.8) 4.6±8.7	(0.1-	35.6)
LH	(mIU/mL) 9.0±4.7	(1.6-	25.9) 10.8±8.7	(0.4-	42.9) 13.3±9.1	(4.0-	28.7) 6.5±4.0	(1.8-	12.4)
FSH	(mIU/mL) 5.9±1.6	(2.4-	13.4) 5.8±2.0	(2.0-	12.1) 5.2±0.9	(4.1-	6.4) 7.6±6.7	(3.9-	32.5)
LH/FSH	ratio 1.6±0.9	(0.3-	5.0) 2.2±2.7	(0.1-	17.2) 2.6±1.8	(1.0-	4.9) 1.0±0.7	(0.3-	3.0)
PRL	(ng/mL) 13.8±7.9	(3.3-	44.3) 16.5±8.5	(2.7-	41.3) 11.0±2.8	(8.7-	15.3) 11.6±6.8	(4.2-	34.4)
Testosterone	(ng/mL) 0.6±0.3	(0.2-	1.3) 1.0±1.6	(0.1-	8.0) 0.6±0.3	(0.4-	1.1) 0.9±0.7	(0.1-	3.1)
DHEA-	S	(ng/mL) 1535±546	(494-	2500) 1717±533	(1030-	2510) 2350±710	(1140-	3600) 1990
E2	(pg/mL) 63.2±58.8	(9.3-	325.0) 85.2±66.5	(3.1-	185.0) 57.0±32.7	(23.0-	101.0) 40.7±10.4	(25.0-	53.4)
C+M	for	CR,	clomiphene–metformin	combination	treatment	for	the	clomiphene-	resistant	patients;	C+M	for	CS,	clomiphene–metformin	combination	treat-
ment	for	the	clomiphene-	sensitive	patients;	C+M	for	naïve,	clomiphene–metformin	combination	treatment	for	the	naïve	patients;	DHEA-	S,	dehydroepian-
drosterone	 sulfate;	 E2,	 estradiol;	 FSH,	 follicle-	stimulating	 hormone;	 HOMA-	IR,	 homeostasis	 model	 assessment	 of	 insulin	 resistance;	 LH,	 luteinizing	
hormone;	M,	metformin	monotherapy;	PRL,	prolactin.
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F IGURE  1 Histogram	of	the	drug	
dosages	with	each	treatment.	A,	Treatment	
1:	clomiphene–metformin	combination	
treatment	for	the	clomiphene-	resistant	
patients.	B,	Treatment	2:	clomiphene–
metformin	combination	treatment	for	the	
clomiphene-	sensitive	patients.	C,	Treatment	
3:	clomiphene–metformin	combination	
treatment	for	the	naïve	patients,	and	D,	
Treatment	4:	metformin	monotherapy.	The	
data	are	expressed	as	the	means±SD
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TABLE  2 Clinical	outcomes
Characteristic C+M for CR C+M for CS C+M for naïve M
Per cycle
Dose	of	clomiphene	(mg/d) 126.3±33.1	(50–200) 98.5±41.6	(50–200) 91.7±46.9	(50–150) –
Dose	of	metformin	(mg/d) 690.1±163.9	(250–1500) 614.4±124.9	(500–750) 520.8±198.2	(250–750) 577.4±151.1	(250–750)
Ovulation	rate	(%) 65.1	(138/212) 91	(181/199) 83.3	(10/12) 75	(27/36)
Number	of	developing	follicles 1.3±0.6	(1-	4) 1.4±1.2	(1-	10) 1.6±1.0	(1-	3) 1.0±0.2	(1-	2)
Rate	of	single	follicular	
development	(%)
81.1	(107/132) 76.1	(140/184) 71.4	(5/7) 95.5	(21/22)
Number	of	days	for	follicular	
development
20.0±6.3	(10–43) 17.3±4.3	(8–39) 20±3.7	(14–25) 18.3±5.3	(11–28)
Pregnancy	(%) 9.9	(21/212) 16.7	(33/198) 62.5	(5/8) 15.6	(5/32)
Abortion	rate	(%) 19	(4/21) 15.6	(5/32) 20	(1/5) 40	(2/5)
Stillbirth	rate	(%) 5.9	(1/17) 0	(0/21) – 0	(0/1)
Multiple	pregnancy	rate	(%) 0	(0/16) 0	(0/23) 0	(0/2) 0	(0/5)
Incidence	of	OHSS	(%) 0	(0/53) 0	(0/59) 0	(0/3) 0	(0/6)
Side-	effects	(%) 5.5 2 0 2.4
Diarrhea	(5),	vomiting	(2),	nausea	
(1),	bad	mood	(1),	liver	
dysfunction	(1),	heartburn	(1),	
eyestrain	(1),	and	uncertain	(3)a
Diarrhea	(2),	nausea	(1),	
and	stomach	ache	(1)
(0/12) Drowsiness	and	general	
fatigue	(1)
(12/217) (4/202) (1/41)
Per case
Ovulation	rate	(%) 69.9	(51/73) 94.3	(50/53) 85.7	(6/7) 60.0	(9/15)
Pregnancy	rate	(%) 21.9	(16/73) 50.9	(27/53) 83.3	(5/6) 33.3	(5/15)
aThere	is	some	overlap.	C+M	for	CR,	clomiphene–metformin	combination	treatment	for	the	clomiphene-	resistant	patients;	C+M	for	CS,	clomiphene–met-
formin	combination	treatment	for	the	clomiphene-	sensitive	patients;	C+M	for	naïve,	clomiphene–metformin	combination	treatment	for	the	naïve	patients;	
M,	metformin	monotherapy;	OHSS,	ovarian	hyperstimulation	syndrome.
     |  183MATSUZAKI eT Al.
HOMA-	IR<0.8	group,	9.1%	in	the	HOMA-	IR=0.8-	1.6	group,	10.0%	
in	 the	HOMA-	IR=1.6-	2.5	 group,	 and	 16.1%	 in	 the	HOMA-	IR≥2.5	
group;	 there	 was	 no	 significant	 difference	 among	 the	 groups,	 al-
though	the	high	HOMA-	IR	group	tended	to	have	a	higher	pregnancy	
rate	than	the	others.
3.2 | Clomiphene–metformin combination treatment 
for the clomiphene- sensitive patients
The	mean	clomiphene	dose	was	98.5±41.6	mg/d.	The	clomiphene	doses	
were	100	mg/d	(54.7%,	111/203)	and	50	mg/d	(28.1%,	57/203),	both	
F IGURE  2 Number	of	days	for	follicular	development	with	each	treatment	(from	the	first	day	of	the	cycle	to	the	day	when	the	follicular	
diameter	reached	18	mm).	A,	Treatment	1:	clomiphene–metformin	combination	treatment	for	the	clomiphene-	resistant	patients.	B,	Treatment	
2:	clomiphene–metformin	combination	treatment	for	the	clomiphene-	sensitive	patients.	C,	Treatment	3:	clomiphene–metformin	combination	
treatment	for	the	naïve	patients,	and	D,	Treatment	4:	metformin	monotherapy
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F IGURE  3 Ovulation	rates	and	
pregnancy	rates	with	the	clomiphene–
metformin	combination	treatment	for	the	
clomiphene-	resistant	patients	(Treatment	
1),	according	to	the	Body	Mass	Index	
(BMI).	*P<.05	vs	BMI=18.5–25	kg/m2 and 
BMI=25–30	kg/m2
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of	which	accounted	for	82.8%	(168/203)	of	the	cycles	for	which	clomi-
phene	was	used	(n=203)	(Table	1,	Figure	1).	The	mean	metformin	dose	
was	614.4±124.9	mg/d.	The	metformin	doses	were	500	mg/d	(54.2%,	
109/201)	and	750	mg/d	(45.8%,	92/201)	in	the	cycles	for	which	met-
formin	was	used	 (n=201).	Most	of	 the	cycles	 (99.5%,	193/194)	were	
treated	with	metformin	continuous	administration,	except	for	one	cycle,	
which	was	treated	with	short-	term	metformin	administration	from	the	
fifth	day	of	the	cycle	to	the	day	of	the	hCG	injection.	The	ovulation	rate	
was	91.0%	per	cycle	and	94.3%	per	case	and	single	follicular	develop-
ment	was	achieved	in	76.1%	of	the	cycles	(Table	2).	The	pregnancy	rate	
was	16.7%	per	cycle	and	50.9%	per	case.	In	the	BMI	subanalysis,	the	
ovulation	rate	per	cycle	was	78.9%	in	the	lean	group,	93.0%	in	the	normal	
group,	89.7%	in	the	overweight	group,	and	97.3%	in	the	obese	group;	
there	was	no	significant	difference	among	the	groups.	Additionally,	the	
pregnancy	 rate	per	 cycle	was	16.7%	 in	 the	 lean	group,	22.0%	 in	 the	
normal	group,	10.3%	in	the	overweight	group,	and	10.8%	in	the	obese	
group;	there	was	no	significant	difference	among	the	groups.	The	ovula-
tion	rate	per	cycle	was	87.5%	in	the	HOMA-	IR<1.6	group,	97.0%	in	the	
HOMA-	IR=1.6-	2.5	group,	and	91.8%	in	the	HOMA-	IR≥2.5	group;	there	
was	 no	 significant	 difference	 among	 the	 groups.	 The	 pregnancy	 rate	
per	cycle	was	17.3%	in	the	HOMA-	IR<1.6	group,	6.1%	in	the	HOMA-	
IR=1.6-	2.5	group,	and	91.8%	in	the	HOMA-	IR≥2.5	group;	there	was	no	
significant	difference	among	the	groups.
3.3 | Clomiphene–metformin combination treatment 
for the naïve patients
The	 mean	 clomiphene	 dose	 was	 91.7±46.9	mg/d.	 The	 clomiphene	
doses	 were	 50	mg/d	 (50.0%,	 6/12)	 and	 150	mg/d	 (33.3%,	 4/12),	
both	of	which	accounted	for	83.3%	of	all	the	treated	cycles	(10/12)	
(Table	1,	Figure	1).	The	mean	metformin	dose	was	520.8±198.2	mg/d.	
The	metformin	 doses	were	 500	mg/d	 (41.7%,	 5/12)	 and	 750	mg/d	
(33.3%,	4/12).	Most	of	the	cycles	(62.5%,	5/8)	were	treated	with	met-
formin	 continuous	 administration	and	 the	others	 (37.5%,	3/8)	were	
treated	with	short-	term	metformin	administration	from	the	fifth	day	
of	the	cycle	to	the	day	of	the	hCG	injection.	The	ovulation	rate	was	
83.3%	per	cycle	and	85.7%	per	case	and	single	follicular	development	
was	achieved	in	71.4%	of	the	cycles	(Table	2).	Although	the	ovulation	
rate	 seemed	high,	 the	usefulness	of	 the	 treatment	was	not	evident	
because	of	the	small	number	of	cases.
3.4 | Metformin monotherapy
There	 were	 several	 reasons	 why	 metformin	 monotherapy	 was	 per-
formed.	The	ovulation	rates	for	the	cycles	and	cases	were	33%	(6/21)	in	
the	clomiphene-	resistant	cases	and	28%	(5/10)	in	the	first-	choice	cases,	
while	22%	(4/7)	of	the	patients	had	an	habitual	abortion	(Table	3).	Two	
(11%)	patients	had	a	high	HOMA-	IR	and	one	of	them	achieved	ovula-
tion	by	clomiphene,	but	not	pregnancy	(6%).	The	mean	metformin	dose	
was	577.4±151.1	mg/d	(Table	1).	The	metformin	doses	were	500	mg/d	
(54.8%,	23/42)	and	750	mg/d	 (38.1%,	16/42)	 (Figure	1).	All	42	cycles	
were	treated	with	metformin	continuous	administration.	The	ovulation	
rate	was	83.3%	per	cycle	in	the	first-	choice	cases,	whereas	it	was	60%	
per	cycle	and	40%	per	case	in	the	clomiphene-	resistant	patients	(Table	3).	
The	pregnancy	rate	was	14.3%	per	cycle	and	25.0%	per	case	in	the	first-	
choice	cases.	There	was	no	pregnancy	in	both	the	cycles	and	cases	in	the	
clomiphene-	resistant	patients.	In	addition,	the	ovulation	rate	per	cycle	
was	0%	 in	 the	HOMA-	IR<1.6	group,	87.0%	 in	 the	HOMA-	IR=1.6-	2.5	
group,	and	85.7%	in	the	HOMA-	IR≥2.5	group.	The	HOMA-	IR<1.6	group	
had	a	significantly	lower	ovulation	rate	than	did	the	other	groups	(P<.05).	
The	usefulness	of	metformin	monotherapy	was	not	clear	because	of	the	
heterogeneous	indications	and	the	small	number	of	cases.
3.5 | Pregnancy outcomes
Multiple	pregnancies	did	not	occur	among	the	42	pregnant	patients	
with	all	metformin	treatments.	Only	one	child	(3.4%,	1/29)	had	a	car-
diac	malformation	among	the	cases	that	were	analyzed.	With	respect	
to	complications	of	pregnancy	in	the	31	pregnant	women,	there	were	
three	cases	of	gestational	diabetes	mellitus,	one	case	of	hypertension,	
one	case	of	premature	 rupture	of	 the	membranes,	 and	one	case	of	
placenta	previa	(19.3%,	6/31)	(Table	4).
3.6 | Incidence of side- effects
Side-	effects	 of	 the	 metformin	 treatments	 were	 observed	 in	 3.6%	
(17/472)	of	the	patients:	diarrhea,	vomiting,	and	stomach	ache	were	
classified	as	digestive	system	dysfunction	(Table	5).	There	was	no	sig-
nificant	 difference	 in	 the	 incidence	of	 adverse	 effects	 between	 the	
three	clomiphene–metformin	combination	treatment	groups	and	the	
metformin	monotherapy	group.
4  | DISCUSSION
Insulin	resistance	is	involved	in	the	pathophysiology	of	PCOS	and	is	more	
common	in	obese,	rather	than	in	non-	obese,	patients	with	PCOS.	Weight	
loss,	exercise,	and	insulin	sensitizers	have	been	proven	to	be	effective	to	
improve	the	pathophysiology	of	PCOS,	including	the	ovulatory	disorder.
Metformin	is	an	oral	hypoglycemic	agent	of	the	biguanide	type,	
which	 inhibits	 gluconeogenesis	 in	 the	 liver,	 promotes	 sugar	 use	 in	
F IGURE  4 Ovulation	rates	and	pregnancy	rates	with	the	
clomiphene–metformin	combination	treatment	for	the	clomiphene-	
resistant	patients	(Treatment	1)	by	fasting	insulin	level.	*P<.05	vs	<15
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the	peripheral	tissue,	and	suppresses	sugar	absorption	in	the	intes-
tinal	tract.	If	a	patient	with	PCOS	is	treated	with	metformin,	insulin	
resistance	is	improved	and	the	serum	insulin	level	is	reduced,	which	
suppresses	ovarian	androgen	production.	 In	2003,	 a	meta-	analysis	
demonstrated	 that	 metformin	 had	 a	 higher	 ovulation	 induction	
effect	 than	 did	 the	 placebo	 in	 PCOS	 (odds	 ratio	 [OR]=3.88,	 95%	
confidence	 interval	 [CI]=2.25-	6.69).7,8	 The	 same	 result	 has	 been	
replicated	in	another	meta-	analysis	(OR=1.81,	95%	CI=1.13-	2.93)	in	
2012.9	The	incidence	of	multiple	pregnancies	in	metformin-	treated	
patients	seems	to	be	lower	than	in	clomiphene-	treated	patients.	For	
example,	 multiple	 pregnancies	 have	 not	 occurred	with	 metformin	
therapy	 in	 Italy,10	whereas	 they	have	occurred	 in	6.0%	of	patients	
in	 the	 USA	 in	 a	 randomized,	 controlled	 trial11	 during	 clomiphene	
therapy.	The	metformin	treatment	was	effective	 in	 inducing	ovula-
tion	or	recovering	the	normal	menstrual	cycle	in	the	lean	or	normal	
BMI	patients	with	PCOS.12–20	 Furthermore,	 some	 reports	have	 in-
dicated	 that	 non-	obese	 (BMI<30	kg/m2)	 patients	with	 PCOS	were	
more	 likely	 to	 respond	 to	 metformin	 than	 obese	 (BMI≥30	kg/m2)	
patients	with	 PCOS	 due	 to	 decreased	 sex	 steroids	 and	 increased	
ovulation	 rates.12,14	 From	 the	 present	 study,	 the	 metformin	 dose	
for	PCOS	in	Japan	was	750	mg/d.	However,	1500-	2500	mg/d	is	fre-
quently	 used	 in	 the	 literature.	 It	was	 reported	 that	 1500	mg/d	 of	
metformin	was	effective	in	87.5%	(7/8)	of	patients	who	did	not	re-
spond	to	750	mg/d	of	metformin	in	clomiphene–metformin	combi-
nation	treatment	for	clomiphene-	resistant	patients.21	In	the	present	
study,	high-	dose	1500	mg/d	metformin	was	used	in	only	two	cases	
with	three	cycles;	it	is	possible	that	a	higher	ovulation	rate	would	be	
obtained	by	a	1500	mg/d	dose	for	patients	who	do	not	respond	to	
750	mg/d	of	metformin.
In	a	meta-	analysis	that	studied	the	clinical	outcome	of	ovulation	in-
duction	in	clomiphene-	resistant	patients	with	PCOS,	adding	metformin	
treatment	showed	significantly	superior	outcomes	to	clomiphene	mono-
therapy	 for	 the	ovulation	 rate	 (OR=6.82,	95%	CI=3.59-	12.96),22	preg-
nancy	rate	 (relative	risk	 [RR]=5.58,	95%	CI=2.34-	13.32),	and	 live	birth	
rate	(RR=6.44,	95%	CI=1.19-	34.90).6	It	was	concluded	that	adding	met-
formin	to	clomiphene	is	extremely	effective	for	patients	with	PCOS	when	
clomiphene	cannot	induce	ovulation.	In	Japanese	clomiphene-	resistant	
patients	with	PCOS,	which	included	many	non-	obese	patients,	the	clo-
miphene–metformin	 combination	 treatment	 showed	 a	 high	 ovulation	
rate,	which	was	calculated	as	≤55.7%	by	combining	several	reports.23–26 
Therefore,	clomiphene–metformin	combination	treatment	seems	to	be	a	
useful	treatment	option	for	clomiphene-	resistant	patients	with	PCOS.	A	
TABLE  3 Clinical	outcomes	of	metformin	monotherapy	by	indication
Clomiphene resistance 
(no ovulation) First choice Habitual abortion
No pregnancy by 
clomiphene in the 
ovulated cycle High HOMA- IR
Number	of	cycles 21 10 7 1 3
Number	of	cases 6 5 4 1 2
Per cycle
Ovulation	rate	(%) 60	(12/20) 83.3	(5/6) 100	(7/7) – 66.7	(2/3)
Number	of	developing	follicles† 1.0±0.0 1.0±0.0 1.0±0.0 2 –
(n=13) (n=2) (n=4) (n=1)
Number	of	days	for	follicular	
developmenta
20.2±5.0	(14–28) 21.4±2.5	(19–25) 14.3±3.7	(12–20) 11 11.5±0.7	(11–12)
Pregnancy	rate	(%) 0	(0/14) 14.3	(1/7) 42.9	(3/7) (0/1) 33.3	(1/3)
Abortion	rate	(%) – 0	(0/1) 66.7	(2/3) – 0	(0/1)
Per case
Ovulation	rate	(%) 40	(2/5) 100	(3/3) 100	(4/4) – 50	(1/2)
Pregnancy	rate	(%) 0	(0/4) 25	(1/4) 75	(3/4) (0/1) 50	(1/2)
aMean±SD.	HOMA-	IR,	homeostasis	model	assessment	of	insulin	resistance.
Outcome Value
Spontaneous	abortion	in	the	first	
trimester	(%)
20.0	(12/60)
Spontaneous	abortion	in	the	second	
trimester	(%)
2.4	(1/41)
Stillbirth	(%) 2.9	(1/35)
Multiple	pregnancy	(%) 0.0	(0/42)
Body	weight	of	the	infant	(g)a	(n=29) 3057.8±527.2	(1807-	4190)
Week	of	delivery	a	(n=29) 39	weeks±12	days
(34	weeks,	3	days-	41	weeks,	
5	days)
Anomaly	in	the	infant	(%) 3.4	(1/29)
Cardiac	malformation	(1)
Complication	during	pregnancy	(%) 19.3	(6/31)
GDM	(3),	hypertension	(1),	
PROM	(1),	placenta	previa	(1)
aMean±SD.	GDM,	gestational	diabetes	mellitus;	PROM,	premature	rupture	
of	the	membranes.
TABLE  4 Pregnancy	outcomes	and	infant	anomalies	in	the	
women	who	conceived	during	the	metformin-	treated	cycles
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BMI	of	>25	kg/m2	or	impaired	glucose	tolerance	and	insulin	resistance,	
even	in	non-	obese	patients,	would	be	good	indications,	considering	met-
formin’s	metabolic	effects.	The	multiple	pregnancy	rate	and	the	incidence	
of	ovarian	hyperstimulation	syndrome	have	been	reported	to	be	lower	
with	 this	 combination	 treatment	 than	with	 clomiphene	 monotherapy	
or	gonadotropin	therapy.	 It	was	mentioned	that	metformin	monother-
apy	was	more	effective	in	patients	who	had	mild	insulin	resistance	and	
were	overweight	than	in	severe	cases.27	In	a	Cochrane	Review	subanal-
ysis,	pregnancy	was	more	easily	obtained	with	metformin	monotherapy	
than	with	clomiphene	monotherapy	in	patients	with	a	BMI	of	<30	kg/
m2	(OR=1.94,	95%	CI=1.19-	3.16).9	Furthermore,	it	was	suggested	that	
patients	with	PCOS	who	were	≥28	years	old	and	patients	with	visceral	
fat	accumulation-	type	obesity	have	a	higher	ability	to	become	pregnant	
with	the	clomiphene–metformin	combination	treatment	than	with	a	clo-
miphene–placebo	combination	therapy.28	Additionally,	in	the	Cochrane	
Review,	ovulation	occurred	more	frequently	with	the	clomiphene–met-
formin	 combination	 treatment	 than	with	 clomiphene	monotherapy	 in	
clomiphene-	resistant	patients	(OR=4.86,	95%	CI=2.43-	9.74).9	However,	
the	factors	that	are	related	to	the	response	to	clomiphene–metformin	
combination	 treatment	 have	 not	yet	 been	 established.	 In	 the	 present	
study,	 the	obese	group	 (BMI>30	kg/m2)	 had	 significantly	higher	preg-
nancy	 rates	 per	 cycle	 and	 per	 case	 with	 the	 clomiphene–metformin	
combination	treatment	in	the	clomiphene-	resistant	patients.	In	addition,	
the	≥15	μU/mL	fasting	 insulin	group	had	significantly	higher	ovulation	
rates	per	cycle	and	pregnancy	rates	per	cycle	and	per	case.	It	seems	that	
clomiphene–metformin	combination	treatment	is	particularly	useful	for	
patients	with	these	backgrounds.	However,	there	were	some	respond-
ers	among	the	patients	with	a	BMI	of	<30	kg/m2	or	a	fasting	insulin	of	
<15	μU/mL.	The	BMI	and	 fasting	 insulin	 are	not	perfect	 as	 factors	 to	
predict	the	response	to	treatment.	 In	addition,	the	HOMA-	IR	was	less	
useful	in	predicting	the	responders.
For	 the	 pregnancy	 outcomes,	 spontaneous	 abortion	 in	 the	 first	
trimester	 occurred	 in	 20%	 (12/60)	 and	 17.5%	 (10/57)	 of	 the	 pa-
tients	 by	 excluding	 habitual	 abortion	with	metformin	monotherapy.	
This	incidence	is	not	high,	considering	that	the	participants	included	
a	relatively	large	number	of	obese	patients.	In	the	Cochrane	Review,	
the	multiple	pregnancy	rate	(OR=0.56,	95%	CI=0.18-	1.68)	and	abor-
tion	rate	(OR=1.61,	95%	CI=1.00-	1.68)	were	not	significantly	different	
between	the	clomiphene–metformin	combination	treatment	and	clo-
miphene	monotherapy	groups.9	Only	one	 infant	had	a	heart	malfor-
mation	and	the	anomaly	rate	seemed	to	be	not	very	high	(3.4%,	1/29	
cases).	With	metformin	monotherapy	and	the	clomiphene–metformin	
combination	 treatments,	 all	 the	 pregnancies	were	 singletons	 in	 the	
present	study.	It	was	reported	that	the	infant	malformation	rate	in	the	
patients	who	took	metformin	in	the	early	pregnancy	period	was	not	el-
evated	for	those	patients	with	PCOS	(OR=0.33,	95%	CI=0.07-	1.56)	or	
for	the	patients	with	diabetes	(OR=.85,	95%	CI=0.14-	5.11),	compared	
to	the	normal	population	in	a	meta-	analysis.29
The	side-	effects	of	metformin	were	mainly	digestive	system	dys-
function	 (5.5%,	12/217	cycles),	 such	as	vomiting	and	diarrhea,	with	
a	 rate	 that	was	 comparable	 to	 that	 seen	 in	 the	 treatment	of	diabe-
tes.	Lactic	acidosis	and	hypoglycemia	are	serious	side-	effects	of	met-
formin	that	did	not	occur	in	the	present	study.	Lactic	acidosis	is	very	
rare,	affecting	three	out	of	10	million	persons	per	year,30	which	is	likely	
to	occur	 in	patients	with	 liver	and	kidney	dysfunction,	and	such	pa-
tients	would	be	few	among	young	women	receiving	fertility	treatment.
The	 clomiphene–metformin	 combination	 treatment	 appears	 to	 be	
useful,	at	least	for	clomiphene-	resistant	patients,	because	of	higher	ovu-
lation	and	pregnancy	rates;	a	BMI	of	>30	kg/m2	or	a	≥15	μU/mL	fasting	
insulin	level	could	be	predictors	of	a	good	response	to	such	treatment.
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Treatment Drug Side- effect (%) Side- effects
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heartburn	(1),	eyestrain	(1),	and	uncertain	(3)a(12/217)
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3.	C+M	for	naïve Clomiphene–metformin 0.0 –
(0/12)
4.	M Metformin 2.0 Drowsiness	and	general	fatigue	(1)
(1/41)
Subtotal	of	1,	2,	
and	3b
Clomiphene–metformin 3.7 –
(16/431)
Total 3.6 –
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aThere	is	some	overlap.	bNo	significant	difference.
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